| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7470 R22266 |
Anderson, 2020 | Any oral cleft | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.00 [0.58;1.73] | -/- 0/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8216 R25605 |
Jordan, 2016 | Oro‐facial clefts | 3 months or more before pregnancy or1st trimester excluded | retrospective cohort (registry) | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
0.55 [0.08;3.91] C excluded (exposition period) |
1/1,069 861/506,155 | 862 | 1,069 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5886 R14750 |
Ban (Controls unexposed, disease free), 2014 | Orofacialcleft | 1st trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.31 [0.02;4.95] C | 0/1,200 438/325,294 | 438 | 1,200 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7228 R20761 |
Davis, 2007 | Cleft palate and cleft lip | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 3.26 [0.44;24.28] | 1/182 92/49,654 | 93 | 182 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.04 [0.62;1.75] | 531 | 1,382 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, disease free;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded